Table 3. Summary of immunohistochemical analyses in apocrine-eccrine carcinomas.
| N | AR | ER | PR | EGFR | HER2 | ||||||
| 1–4+ | 0 | 1–4+ | 0 | 1–4+ | 0 | Low/High | 0 | 2+ | 1+/0 | ||
| Apocrine carcinoma | 10 | 9 | 0 | 5 | 4 | 2 | 7 | 5 | 5 | 3 | 7 |
| Eccrine carcinoma | 7 | 0 | 7 | 1 | 6 | 3 | 4 | 6 | 1 | 0 | 7 |
| Aggressive digital papillary adenocarcinoma | 9 | 6 | 3 | 2 | 7 | 1 | 8 | 9 | 0 | 1 | 8 |
| Hidradenocarcinoma | 10 | 2 | 8 | 1 | 9 | 1 | 9 | 9 | 1 | 1 | 9 |
| Porocarcinoma | 11 | 3 | 8 | 5 | 4 | 0 | 9 | 9 | 0 | 0 | 9 |
| Adenoid cystic carcinoma | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 |
| Malignant chondroid syringoma | 4 | 3 | 1 | 1 | 3 | 1 | 3 | 3 | 1 | 1 | 3 |
| Malignant spiradenoma | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 |
| Malignant cylindroma | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
| Total | 54 | 23/53 (43%) | 30/53 (57%) | 17/51 (33%) | 34/51 (67%) | 10/51 (20%) | 41/51 (80%) | 44/52 (85%) | 8/52 (15%) | 6/52 (12%) | 46/52 (88%) |